Author

T. Karakousi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Herrera· 2 shared A. Rashidfarrokhi· 2 shared A. Tsirigos· 2 shared C. M. Rudin· 2 shared E. Ivanova· 2 shared K. M. Khanna· 2 shared K.-k. Wong· 2 shared R. Pillai· 2 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Herrera

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer

R. Pillai, S. E. LeBoeuf, Y. Hao, C. New, J. Blum, A. Rashidfarrokhi, S. M. Huang, C. Bahamon, W. L. Wu, B. Karadal-Ferrena, A. Herrera, E. Ivanova, M. Cross, J. P. Bossowski, H. Ding, , T. Papagiannakopoulos

This study shows that DRP-104, a glutamine antagonist, suppresses KEAP1 mutant lung tumor growth and enhances response to checkpoint blockade by inhibiting glutamine metabolism and improving T cell function.

bioRxiv · Jun 27, 2023 · PreprintCancer Biology

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

A. M. Zavitsanou, Y. Hao, W. L. Wu, E. Bartnicki, R. Pillai, T. Karakousi, A. Herrera, A. Karatza, A. Rashidfarrokhi, S. Solis, M. Ciampricotti, A. H. Yeaton, E. Ivanova, C. A. Wohlhieter, T. B. Buus, , S. B. Koralov

This study shows KEAP1 mutations in lung adenocarcinoma lead to immune evasion by reducing dendritic cell and T cell responses, contributing to immunotherapy resistance.

bioRxiv · Sep 24, 2021 · PreprintCancer Biology